A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setti
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This multicenter, open-label study was designed to evaluate real-world effectiveness and ease of use of nasal glucagon (NG) in treating moderate or severe hypoglycemic events in children and adolescents with type 1 diabetes (T1D). METHODS: Caregivers were trained to administer NG (3 mg) to the child/adolescent with T1D during spontaneous, symptomatic moderate or severe hypoglycemic events, observe treatment response (defined as awakening or returning to normal status within 30 minutes), and measure blood glucose (BG) levels every 15 minutes. Data regarding adverse events and ease of use were solicited using questionnaires. RESULTS: The analysis population included 14 patients who experienced 33 moderate hypoglycemic events with neuroglycopenic symptoms and BG level ≤70 mg/dL. Patients returned to normal status within 30 minutes of NG administration in all 33 events. Mean BG levels increased from 55.5 mg/dL (range 42-70 mg/dL) at baseline to 113.7 mg/dL (range 79-173 mg/dL) within 15 minutes of NG administration. In most hypoglycemic events (93.9%), caregivers reported that NG administration was easy or very easy; they could administer NG within 30 seconds in 60.6% of events. There were no serious adverse events. CONCLUSIONS: A single 3-mg dose of NG was effective in treating moderate, symptomatic, hypoglycemic events in children and adolescents with T1D in a real-world setting. It was easy-to-use and reasonably well tolerated. NG shows promise as an effective, needle-free, and user-friendly alternative to injectable glucagon.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Clarke, W. L., Cox, D. J., Gonder-Frederick, L. A., Julian, D., Schlundt, D., & Polonsky, W. (1995) · Diabetes Care · doi:10.2337/diacare.18.4.517 · Cited by 651
International Hypoglycaemia Study Group (2017) · Diabetes Care · doi:10.2337/dc16-2215 · Cited by 608
Fear of hypoglycaemia in parents of young children with type 1 diabetes: A systematic review
Barnard, K., Thomas, S., Royle, P., Noyes, K., & Waugh, N. (2010) · BMC Pediatrics · doi:10.1186/1471-2431-10-50 · Cited by 239
Haynes, A., Hermann, J. M., Miller, K. M., Hofer, S. E., Jones, T. W., Beck, R. W., Maahs, D. M., Davis, E. A., Holl, R. W., & for the T1D Exchange, W. A. D. R. (2017) · Pediatric Diabetes · doi:10.1111/pedi.12477 · Cited by 88
Yale, J.-F., Dulude, H., Egeth, M., Piché, C. A., Lafontaine, M., Carballo, D., Margolies, R., Dissinger, E., Shames, A. R., Kaplowitz, N., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0460 · Cited by 88
Self-citation
Cited by
Suico, J. G., Hövelmann, U., Zhang, S., Shen, T., Bergman, B., Sherr, J., Zijlstra, E., Frier, B. M., & Plum-Mörschel, L. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00845-7 · Cited by 32
Self-citationGuzman, C. B., Dulude, H., Piché, C., Rufiange, M., Sadoune, A. A., Rampakakis, E., Carballo, D., Triest, M., Zhang, M. X., Zhang, S., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13134 · Cited by 28
Self-citationMatsuhisa, M., Takita, Y., Nasu, R., Nagai, Y., Ohwaki, K., & Nagashima, H. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14019 · Cited by 27
Pontiroli, A. E., & Tagliabue, E. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01483-y · Cited by 25
Hypoglycaemia and its management in primary care setting
Ibrahim, M., Baker, J., Cahn, A., Eckel, R. H., El Sayed, N. A., Fischl, A. H., Gaede, P., Leslie, R. D., Pieralice, S., Tuccinardi, D., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3332 · Cited by 21
Metadata
- Authors
- Deeb, L. C., Dulude, H., Guzman, C. B., Zhang, S., Reiner, B. J., Piché, C. A., Pradhan, S., & Zhang, X. M.
- Venue
- Pediatric Diabetes
- Publisher
- Wiley
- Published
- 2018-03-22
- Volume
- 19
- Issue
- 5
- Pages
- 1007-1013
- ISSN
- 1399-543X (ISSN-L)
- OpenAlex
- W2790016776
- Cited by
- 50
- References
- 6
- FWCI
- 4.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setti. https://app.cochat.ai/papers/10.1111/pedi.12668
- The paper
- Deeb, L. C., Dulude, H., Guzman, C. B., Zhang, S., Reiner, B. J., Piché, C. A., Pradhan, S., & Zhang, X. M. (2018). A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setti. Pediatric Diabetes. https://doi.org/10.1111/pedi.12668
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.